The 9 references in paper L. Krasnykh M., V. Smirnov V., E. Egorenkov A., G. Vasilenko F., S. Dementyev P., G. Ramenskaya V., Л. Красных М., В. Смирнов В., Е. Егоренков А., Г. Василенко Ф., С. Дементьев П., Г. Раменская В. (2018) “Сравнительное изучение фармакокинетики периндоприла и его метаболита с помощью разработанного метода ВЭЖХ/МС // Comparative study of perindopril and perindopril metabolite pharmacokinetics using the HPLC/MS method” / spz:neicon:vedomostincesmp:y:2015:i:1:p:21-25

1
Russian national guidelines for the diagnosis and treatment of hypertension. Second revision. Kardiovaskulyarnaya terapiya i profilaktika 2004; (6) (in Russian).
(check this in PDF content)
2
Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003; (289): 2560–72.
(check this in PDF content)
3
Zhuchkova, Litsareva EA, Samoylova EL, Spivak NL, eds. Vidal handbook. Moscow: AstraFarmServis; 2003 (in Russian).
(check this in PDF content)
4
Nirogi RV et al. High-throughput quantification of perindopril in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study. Rapid Commun Mass Spectrom. 2006; 20(12): 1864–70.
(check this in PDF content)
5
Jain DS et al. First LC-MS/MS electrospray ionization validated method for the quantification of perindopril and its metabolite perindoprilat in human plasma and its application to bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 837(1–2): 92–100.
(check this in PDF content)
6
Louis WJ, Workman BS, Conway EL et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril inhypertensive subjects. J Cardiovasc Pharmacol. 1992; 20(3): 505–11. R E F E R E N C E S Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation, 8 Petrovsky Boulevard, Moscow, 127051, Russian Federation. Krasnykh LM. Head of Clinical Pharmacokinetics Department of Clinical Pharmacology Center. Candidate of Biological Sciences. Smirnov VV. Leading researcher of Clinical Pharmacokinetics Department of Clinical Pharmacokinetics Department of Clinical Pharmacology Center. Candidate of Pharmaceutical Sciences. Vasilenko GF. Leading researcher of Clinical Phar
(check this in PDF content)
7
Berg H, Resplandy G, de Bie AT et al. A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. J Pharm Biomed Anal. 1991; 9(7): 517–24.
(check this in PDF content)
8
Maurer HH, Kraemer T, Arlt JW. Screening for the detection of angiotensin-converting enzyme inhibitors, their metabolites, and AT II receptor antagonists. Ther Drug Monit. 1998; 20(6): 706–13.
(check this in PDF content)
9
Проведение качественных исследований биоэквивалентности лекарственных средств. Методические указания. Минздравсоцразвития РФ; 2008. 7. Van den Berg H, Resplandy G, de Bie AT et al. A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor perin-
(check this in PDF content)